Compare Merck & Co., Inc. (MRK) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance

Merck & Co., Inc.Trade

Royalty Pharma plc Class A Ordinary SharesTrade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Merck & Co., Inc. trades at $146.44 (market cap $351.28B), while Royalty Pharma plc Class A Ordinary Shares trades at $57.06 (market cap $25.27B). The key difference: Merck & Co., Inc. is far larger — about 13.9× Royalty Pharma plc Class A Ordinary Shares's market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.

	MRK	RPRX
Market Cap	$351.28B	$25.27B
Volume	7,969,665	3,671,183
Sector	Health	Health
52-Week High	$156.43	$63.96
52-Week Low	$82.49	$35.44
Typical Hold Time	98 Days	1 Days
Enterprise Value	$398.04B	$32.50B
Dividend Yield	2.39%	1.66%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.

The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.

Royalty Pharma plc Class A Ordinary Shares

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MRK

18% Buy82% Sell

Avg holding period · 98 Days

RPRX

No sentiment data available yet.

Top news

Latest headlines on both assets

MRK

Cantor Fitzgerald raises price targets on Eli Lilly, AbbVie, Merck, and Pfizer amid mixed growth outlooks.24/7 Wall Street · 9 hours agoBullish Global DPP-4 inhibitors market to grow to $15.5B by 2032, driven by type 2 diabetes demand and generics expansion.PRNewsWire · 1 day agoNeutral HP, Merck, and Seagate paid dividends on Oct 7, with Merck leading in per-share payout and HP offering the highest yield.24/7 Wall Street · 1 day agoBullish View details →

RPRX

Royalty Pharma to release Q3 2026 earnings on Nov 4 with live webcast and call.GlobeNewsWire · 9 hours agoNeutral View details →

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

About Royalty Pharma plc Class A Ordinary Shares

Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.